- Home
- DATS vs BCDA Comparison
DATS vs BCDA Comparison
Compare DATS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- BCDA
- Stock Information
- Founded
- DATS 2014
- BCDA N/A
- Country
- DATS United States
- BCDA United States
- Employees
- DATS N/A
- BCDA N/A
- Industry
- DATS Computer Software: Prepackaged Software
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- BCDA Health Care
- Exchange
- DATS Nasdaq
- BCDA Nasdaq
- Market Cap
- DATS 10.4M
- BCDA 10.1M
- IPO Year
- DATS 2021
- BCDA N/A
- Fundamental
- Price
- DATS $2.49
- BCDA $2.16
- Analyst Decision
- DATS
- BCDA Strong Buy
- Analyst Count
- DATS 0
- BCDA 1
- Target Price
- DATS N/A
- BCDA $25.00
- AVG Volume (30 Days)
- DATS 175.0K
- BCDA 78.3K
- Earning Date
- DATS 05-15-2025
- BCDA 05-14-2025
- Dividend Yield
- DATS N/A
- BCDA N/A
- EPS Growth
- DATS N/A
- BCDA N/A
- EPS
- DATS N/A
- BCDA N/A
- Revenue
- DATS $388.00
- BCDA $3,000.00
- Revenue This Year
- DATS N/A
- BCDA N/A
- Revenue Next Year
- DATS N/A
- BCDA N/A
- P/E Ratio
- DATS N/A
- BCDA N/A
- Revenue Growth
- DATS N/A
- BCDA N/A
- 52 Week Low
- DATS $1.01
- BCDA $1.63
- 52 Week High
- DATS $9.34
- BCDA $5.69
- Technical
- Relative Strength Index (RSI)
- DATS 46.44
- BCDA 46.19
- Support Level
- DATS $2.43
- BCDA $1.80
- Resistance Level
- DATS $2.86
- BCDA $2.92
- Average True Range (ATR)
- DATS 0.19
- BCDA 0.23
- MACD
- DATS 0.00
- BCDA -0.04
- Stochastic Oscillator
- DATS 32.73
- BCDA 32.14
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).